Assessing early signs of relapse in psychosis: Review and future directions

Clinical Psychology Review

Volumn 33, Issue 5, 2013, Pages 637-653

  Eisner, Emily ^a   Drake, Richard ^a   Barrowclough, Christine ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Basic symptoms; Early signs; Prodrome; Psychosis; Relapse; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

BRIEF PSYCHIATRIC RATING SCALE; COCHRANE LIBRARY; COGNITIVE THERAPY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DSM-III; EMBASE; FALSE POSITIVE RESULT; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAINTENANCE THERAPY; MEDLINE; PATIENT COMPLIANCE; PATIENT MONITORING; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALUE; PSYCHOSIS; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TARDIVE DYSKINESIA;

HUMANS; PSYCHOTIC DISORDERS; RECURRENCE; SCHIZOPHRENIA;

EID: 84877017576     PISSN: 02727358     EISSN: 18737811     Source Type: Journal    
DOI: 10.1016/j.cpr.2013.04.001     Document Type: Review

References (104)

1. Almond S., Knapp M., Francois C., Toumi M., Traolach B. Relapse in schizophrenia: Costs, clinical outcomes and quality of life. The British Journal of Psychiatry 2004, 184:346-351.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: Proposed criteria and rationale for consensus. The American Journal of Psychiatry 2005, 162:441-449.
3. Bebbington P.E., Craig T., Garety P., Fowler D., Dunn G., Colbert S., et al. Remission and relapse in psychosis: Operational definitions based on case-note data. Psychological Medicine 2006, 36:1551-1562.
4. Bechdolf A., Schultze-Lutter F., Klosterkötter J. Self-experienced vulnerability, prodromal symptoms and coping strategies preceding schizophrenic and depressive relapses. European Psychiatry 2002, 17:384-393.
5. Bewick V., Cheek L., Ball J. Statistics review 13: Receiver operating characteristic curves. Critical Care 2004, 8:508-512.
6. Birchwood M. Early intervention in psychotic relapse: Cognitive approaches to detection and management. Behaviour Change 1995, 12:2-19.
7. Birchwood M., Smith J., Macmillan F., Hogg B., Prasad R., Harvey C., et al. Predicting relapse in schizophrenia: The development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychological Medicine 1989, 19:649-656.
8. Birchwood M., Spencer E. Early intervention in psychotic relapse. Clinical Psychology Review 2001, 21:1211-1226.
9. Birchwood M., Spencer E., McGovern D. Schizophrenia: Early warning signs. Advances in Psychiatric Treatment 2000, 6:93-101.
10. Brown G.W., Birley J.L.T., Wing J.K. Influence of family life on the course of schizophrenic disorders: A replication. The British Journal of Psychiatry 1972, 121:241-258.
11. Burns T., Fiander M., Audini B. A Delphi approach to characterising 'relapse' as used in UK clinical practice. The International Journal of Social Psychiatry 2000, 46:220-230.
12. Carpenter W.T., Hanlon T.E., Heinrichs D.W., Summerfelt A.T., Kirkpatrick B., Levine J., et al. Continuous versus targeted medication in schizophrenic outpatients: Outcome results. The American Journal of Psychiatry 1990, 147:1138-1148.
13. Carpenter W.T., Heinrichs D.W. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophrenia Bulletin 1983, 9:533-542.
14. Carpenter W.T., Heinrichs D.W., Hanlon T.E. A comparative trial of pharmacologic strategies in schizophrenia. The American Journal of Psychiatry 1987, 144:1466-1470.
15. Chapman J. The early symptoms of schizophrenia. The British Journal of Psychiatry 1966, 112:225-251.
16. D'Agostino R.B., Massaro J.M., Sullivan L.M. Non-inferiority trials: Design concepts and issues - The encounters of academic consultants in statistics. Statistics in Medicine 2003, 22:169-186.
17. Dunn G., Fowler D., Rollinson R., Freeman D., Kuipers E., Smith B., et al. Effective elements of cognitive behaviour therapy for psychosis: Results of a novel type of subgroup analysis based on principal stratification. Psychological Medicine 2012, 42:1057-1068.
18. Falloon I.R., Marshall G.N., Boyd J.L., Razani J., Wood-Siverio C. Relapse in schizophrenia: A review of the concept and its definitions. Psychological Medicine 1983, 13:469-477.
19. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., et al. Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 2012, 69:220-229.
20. Gaebel W., Frick U., Kopcke W., Linden M., Muller P., Muller-Spahn F., et al. Early neuroleptic intervention in schizophrenia: Are prodromal symptoms valid predictors of relapse?. The British Journal of Psychiatry. Supplement 1993, 8-12.
21. Gaebel W., Janner M., Frommann N., Pietzcker A., Kopcke W., Linden M., et al. First vs multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research 2002, 53:145-159.
22. Gaebel W., Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophrenia Research 2007, 95:19-29.
23. Gaebel W., Riesbeck M., Wolwer W., Klimke A., Eickhoff M., Von Wilmsdorff M., et al. Relapse prevention in first-episode schizophrenia - Maintenance vs intermittent drug treatment with prodrome-based early intervention: Results of a randomized controlled trial within the German research network on schizophrenia. The Journal of Clinical Psychiatry 2011, 72:205-218.
24. Garety P., Fowler D.G., Freeman D., Bebbington P., Dunn G., Kuipers E. Cognitive-behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: Randomised controlled trial. The British Journal of Psychiatry 2008, 192:412-423.
25. Garety P., Kuipers E., Fowler D., Freeman D., Bebbington P. A cognitive model of the positive symptoms of psychosis. Psychological Medicine 2001, 31:189-195.
26. Gleeson J.F., Alvarez-Jimenez M., Cotton S.M., Parker A.G., Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophrenia Research 2010, 119:79-88.
27. Gleeson J.F., Rawlings D., Jackson H.J., McGorry P.D. Early warning signs of relapse following a first episode of psychosis. Schizophrenia Research 2005, 80:107-111.
28. Gross G. Prodrome und Vorpostensyndrome schizophrener Erkrankungen. Schizophrenie und Zyklothymie 1969, 177-187. Thieme, Stuttgart. G. Huber (Ed.).
29. Gross G. The 'basic' symptoms of schizophrenia. The British Journal of Psychiatry. Supplement 1989, 21-25. (discussion 37-40).
30. Gross G., Huber G. The history of the basic symptom concept. Acta Clinica Croatica 2010, 49:47-59.
31. Gumley A., O'Grady M., McNay L., Reilly J., Power K., Norrie J. Early intervention for relapse in schizophrenia: Results of a 12-month randomized controlled trial of cognitive behavioural therapy. Psychological Medicine 2003, 33:419-431.
32. Gumley A., Power K. Is targeting cognitive therapy during relapse in psychosis feasible?. Behavioural and Cognitive Psychotherapy 2000, 28:161-174.
33. Gumley A., White C., Power K. An Interacting Cognitive Subsystems model of relapse and the course of psychosis. Clinical Psychology & Psychotherapy 1999, 6:261-278.
34. Hafner H., an der Heiden W., Behrens S., Gattaz W.F., Hambrecht M., Loffler W., et al. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophrenia Bulletin 1998, 24:99-113.
35. Harrow M., Jobe T.H. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A 15-year multifollow-up study. The Journal of Nervous and Mental Disease 2007, 195:406-414.
36. Herz M.I., Glazer W.M., Mostert M.A., Sheard M.A., Szymanski H.V., Hafez H., et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry 1991, 48:333-339.
37. Herz M.I., Lamberti J.S., Mintz J., Scott R., O'Dell S.P., McCartan L., et al. A program for relapse prevention in schizophrenia: A controlled study. Archives of General Psychiatry 2000, 57:277-283.
38. Herz M.I., Melville C. Relapse in schizophrenia. The American Journal of Psychiatry 1980, 137:801-805.
39. Hirsch S., Jolley A. The dysphoric syndrome in schizophrenia and its implications for relapse. The British Journal of Psychiatry. Supplement 1989, 5:46-50.
40. Huber G., Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Progressi in Medicina 1989, 80:646-652.
41. Johnstone E.C. Relapse in schizophrenia: What are the major issues?. Practical problems in clinical psychiatry 1992, 159-171. Oxford University Press, Oxford. K. Hawton (Ed.).
42. Johnstone E.C., Crow T.J., Frith C.D., Carney M.W., Price J.S. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978, 1:848-851.
43. Jolley A.G., Hirsch S.R., Morrison E., McRink A., Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years. BMJ 1990, 301:837-842.
44. Jørgensen Early signs of psychotic relapse in schizophrenia. The British Journal of Psychiatry 1998, 172:327.
45. Kane J.M., Woerner M., Borenstein M., Wegner J., Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin 1986, 22:254-258.
46. Kane J.M., Woerner M., Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988, 8:52S-56S.
47. Kimhy D., Myin-Germeys I., Palmier-Claus J., Swendsen J. Mobile assessment guide for research in schizophrenia and severe mental disorders. Schizophrenia Bulletin 2012, 38:386-395.
48. Klosterkötter J., Ebel H., Schultze-Lutter F., Steinmeyer E.M. Diagnostic validity of basic symptoms. European Archives of Psychiatry and Clinical Neuroscience 1996, 246:147-154.
49. Klosterkötter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry 2001, 58:158-164.
50. Klosterkötter J., Schultze-Lutter F., Bechdolf A., Ruhrmann S. Prediction and prevention of schizophrenia: What has been achieved and where to go next?. World Psychiatry 2011, 10:165-174.
51. Klosterkötter J., Schultze-Lutter F., Gross G., Huber G., Steinmeyer E.M. Early self-experienced neuropsychological deficits and subsequent schizophrenic diseases: An 8-year average follow-up prospective study. Acta Psychiatrica Scandinavica 1997, 95:396-404.
52. Korver N., Nieman D.H., Becker H.E., van de Fliert J.R., Dingemans P.H., de Haan L., et al. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. The Australian and New Zealand Journal of Psychiatry 2010, 44:230-236.
53. Lader M. What is relapse in schizophrenia?. International Clinical Psychopharmacology 1995, 9:5-9.
54. Lee S.H., Choi T.K., Suh S., Kim Y.W., Kim B., Lee E., et al. Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection. Psychiatry Research 2010, 175:195-199.
55. Leff J., Kuipers L., Berkowitz R., Eberlein-Vries R., Sturgeon D. A controlled trial of social intervention in the families of schizophrenic patients. The British Journal of Psychiatry 1982, 141:121-134.
56. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. The American Journal of Psychiatry 2003, 160:1209-1222.
57. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. The American Journal of Psychiatry 2009, 166:152-163.
58. Lynch D., Laws K.R., McKenna P.J. Cognitive behavioural therapy for major psychiatric disorder: Does it really work? A meta-analytical review of well-controlled trials. Psychological Medicine 2010, 40:9-24.
59. Maclean C. An interpretative phenomenological analysis of service users' perspectives and experiences of relapse in psychosis 2008, University of Glasgow.
60. Malla A.K., Norman R.M. Prodromal symptoms in schizophrenia. The British Journal of Psychiatry 1994, 164:487-493.
61. Mangalore R., Knapp M. Cost of schizophrenia in England. The Journal of Mental Health Policy and Economics 2007, 10:23-41.
62. Marder S., Mintz J., Van Putten T., Lebell M., Wirshing W., Johnston-Cronk K. Early prediction of relapse in schizophrenia: An application of receiver operating characteristic (ROC) methods. Psychopharmacology Bulletin 1991, 27:79-82.
63. Marder S., Wirshing W., Van Putten T., Mintz J., McKenzie J., Johnston-Cronk K., et al. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Archives of General Psychiatry 1994, 51:280-287.
64. McGorry P.D., Nelson B., Amminger G.P., Bechdolf A., Francey S.M., Berger G., et al. Intervention in individuals at ultra-high risk for psychosis: A review and future directions. The Journal of Clinical Psychiatry 2009, 70:1206-1212.
65. Meng H., Schimmelmann B.G., Koch E., Bailey B., Parzer P., Gunter M., et al. Basic symptoms in the general population and in psychotic and non-psychotic psychiatric adolescents. Schizophrenia Research 2009, 111:32-38.
66. NICE Core interventions in the treatment and management of schizophrenia in primary and secondary care (update) 2009, National Institute for Health and Clinical Excellence, London.
67. Nuechterlein K.H., Miklowitz D.J., Ventura J., Gitlin M.J., Stoddard M., Lukoff D. Classifying episodes in schizophrenia and bipolar disorder: Criteria for relapse and remission applied to recent-onset samples. Psychiatry Research 2006, 144:153-166.
68. Olsen K.A., Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: Assessment instruments. Acta Psychiatrica Scandinavica 2006, 113:273-282.
69. Parnas J., Handest P., Jansson L., Saebye D. Anomalous subjective experience among first-admitted schizophrenia spectrum patients: Empirical investigation. Psychopathology 2005, 38:259-267.
70. Parnas J., Handest P., Saebye D., Jansson L. Anomalies of subjective experience in schizophrenia and psychotic bipolar illness. Acta Psychiatrica Scandinavica 2003, 108:126-133.
71. Peralta V., Cuesta M.J. Subjective experiences in psychotic disorders: Diagnostic value and clinical correlates. Comprehensive Psychiatry 1998, 39:11-15.
72. Pietzcker A., Gaebel W., Köpcke W., Linden M., Müller P., Müller-Spahn F., et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-Year results of a German multicentre study. Journal of Psychiatric Research 1993, 27:321-339.
73. Pilling S., Bebbington P., Kuipers E., Garety P., Geddes J., Orbach G., et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine 2002, 32:763-782.
74. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 1999, 56:241-247.
75. Ruhrmann S., Schultze-Lutter F., Salokangas R.K., Heinimaa M., Linszen D., Dingemans P., et al. Prediction of psychosis in adolescents and young adults at high risk: Results from the prospective European prediction of psychosis study. Archives of General Psychiatry 2010, 67:241-251.
76. Ruskin P., Bland W., Feldman S. Continuous vs. targeted medication in older schizophrenic outpatients. The American Journal of Geriatric Psychiatry 1994, 2:134-143.
77. Sass L.A., Parnas J. Phenomenology of self-disturbances in schizophrenia: Some research findings and directions. Philosophy, Psychiatry and Psychology 2001, 8:347-356.
78. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Archives of General Psychiatry 1997, 54:453-463.
79. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: The basic symptom concept. Schizophrenia Bulletin 2009, 35:5-8.
80. Schultze-Lutter F., Addington J., Ruhrmann S., Klosterkötter J. Schizophrenia Proneness Instrument: Adult Version (SPI-A) 2007, Giovanni Fioriti Editore, Rome, Italy.
81. Schultze-Lutter F., Klosterkötter J., Picker H., Steinmeyer E.M., Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. Clinical Neuropsychiatry 2007, 4:11-22.
82. Schultze-Lutter F., Michel C., Schimmelmann B.G. Prevalence of at-risk criteria of psychosis in the general population: Preliminary results from a telephone survey. 3rd Schizophrenia International Research Society Conference. Florence, Italy 2012.
83. Schultze-Lutter F., Ruhrmann S., Berning J., Maier W., Klosterkötter J. Basic symptoms and ultrahigh risk criteria: Symptom development in the initial prodromal state. Schizophrenia Bulletin 2010, 36:182-191.
84. Schultze-Lutter F., Ruhrmann S., Fusar-Poli P., Bechdolf A., Schimmelmann B.G., Klosterkötter J. Basic symptoms and the prediction of first-episode psychosis. Current Pharmaceutical Design 2012, 18:351-357.
85. Schultze-Lutter F., Ruhrmann S., Picker H., von Reventlow H.G., Brockhaus-Dumke A., Klosterkötter J. Basic symptoms in early psychotic and depressive disorders. The British Journal of Psychiatry. Supplement 2007, 51:s31-s37.
86. Schultze-Lutter F., Steinmeyer E.M., Ruhrmann S., Klosterkötter J. The dimensional structure of self-reported 'prodromal' disturbances in schizophrenia. Clinical Neuropsychiatry 2008, 5:140-150.
87. Simon A.E., Dvorsky D.N., Boesch J., Roth B., Isler E., Schueler P., et al. Defining subjects at risk for psychosis: A comparison of two approaches. Schizophrenia Research 2006, 81:83-90.
88. Stenberg J., Jaaskelainen I., Royks R. The effect of symptom self-management training on rehospitalization for chronic schizophrenia in Finland. International Review of Psychiatry 1998, 10:58-61.
89. Stephens J.H. Long-term prognosis and followup in schizophrenia. Schizophrenia Bulletin 1978, 4:25-47.
90. Stephens J.H., Richard P., McHugh P.R. Long-term follow-up of patients hospitalized for schizophrenia, 1913 to 1940. The Journal of Nervous and Mental Disease 1997, 185:715-721.
91. Subotnik K., Neuchterlein K. Prodromal signs and symptoms of schizophrenic relapse. Journal of Abnormal Psychology 1988, 97:405-412.
92. Tait A., McNay L., Gumley A., O'Grady M. The development and implementation of an individualised early signs monitoring system in the prediction of relapse in schizophrenia. Journal of Mental Health 2002, 11:141-153.
93. Tarrier N., Barrowclough C., Bamrah J.S. Prodromal signs of relapse in schizophrenia. Social Psychiatry and Psychiatric Epidemiology 1991, 26:157-161.
94. The Schizophrenia Commission The abandoned illness: A report from the Schizophrenia Commission 2012, Rethink Mental Illness, London.
95. Vaillant G.E. 10-Year followup of remitting schizophrenics. Schizophrenia Bulletin 1978, 4:78-85.
96. van Meijel B., Kruitwagen C., van der Gaag M., Kahn R.S., Grypdonck M.H. An intervention study to prevent relapse in patients with schizophrenia. Journal of Nursing Scholarship 2006, 38:42-49.
97. van Meijel B., van der Gaag M., Kahn R.S., Grypdonck M. The practice of early recognition and early intervention to prevent psychotic relapse in patients with schizophrenia: An exploratory study. Part 1. Journal of Psychiatric and Mental Health Nursing 2002, 9:347-355.
98. van Meijel B., van der Gaag M., Kahn R.S., Grypdonck M.H. Recognition of early warning signs in patients with schizophrenia: A review of the literature. International Journal of Mental Health Nursing 2004, 13:107-116.
99. van Meijel B., van der Gaag M., Kahn R.S., Grypdonck M. The practice of early recognition and early intervention to prevent psychotic relapse in patients with schizophrenia: An exploratory study. Part 2. Journal of Psychiatric and Mental Health Nursing 2002, 9:357-363.
100. Varsamis J., Adamson J.D. Early schizophrenia. Canadian Psychiatric Association Journal 1971, 16:487-497.
101. Wiedemann G., Hahlweg K., Muller U., Feinstein E., Hank G., Dose M. Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2001, 251:72-84.
102. Wiersma D., Nienhuis F., Slooff C., Giel R. Natural course of schizophrenic disorders: A 15-year followup of a Dutch incidence cohort. Schizophrenia Bulletin 1998, 24:75-85.
103. Wunderink L., Nienhuis F.J., Sytema S., Slooff C.J., Knegtering R., Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: Relapse rates and functional outcome. The Journal of Clinical Psychiatry 2007, 68:654-661.
104. Yung A. Identification and treatment of the prodromal phase of psychotic disorders: Perspectives from the PACE Clinic. Early Intervention in Psychiatry 2007, 1:224-235.